Galmed Pharmaceutica (GLMD)

$0.51 -0.03 (-5.73%)
Market Cap 2.99M
Revenue (ttm) 0.00
Net Income (ttm) -10.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 177,272
Avg Vol 875,468
Day's Range N/A - N/A
Shares Out 5.48M
Stochastic %K 67%
Beta 0.75
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Stu...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
Mile111
Mile111 Jul. 20 at 8:16 AM
$GLMD next week delisting 🫡
0 · Reply
Lowlyme
Lowlyme Jul. 19 at 10:52 PM
$GLMD Allen. Divert money from primary drug candidate. Wait 6 months while memories fade. Pay yourself. Repeat.
0 · Reply
Lowlyme
Lowlyme Jul. 19 at 10:27 PM
$GLMD I've seen more UFO's in the past five years than I've heard from Allen. LM
0 · Reply
YaKnowImRight
YaKnowImRight Jul. 17 at 10:06 PM
$GLMD Sitting here wondering exactly what it's gonna take for this to get reasonably valued in the market. A $4.23M MC is absurd for what glmd has.
2 · Reply
Lowlyme
Lowlyme Jul. 17 at 1:43 PM
$GLMD If so I wonder why not just let us know? Anyway, hope so soon. GLTA LM
1 · Reply
madan_shatri
madan_shatri Jul. 17 at 12:57 PM
$GLMD no news about reverse split so it looks like they've got the extension. I am ok on extension rather than reverse split
1 · Reply
Vermont512
Vermont512 Jul. 17 at 9:00 AM
$GLMD I hope the upward trend from yesterday continues today.😉
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Jul. 16 at 11:37 PM
$GLMD on watch
0 · Reply
YaKnowImRight
YaKnowImRight Jul. 16 at 10:33 PM
$GLMD Actually closed up. Can we get a follow-through tomorrow?
0 · Reply
Mile111
Mile111 Jul. 16 at 8:12 PM
$GLMD why this Not going 100 Dollar whyyyyyyyyyyy???????
0 · Reply
Latest News on GLMD
Galmed announces development of novel LNP cardiac targeted Aramchol formulation

2026-07-16T11:45:37.000Z - 4 days ago

Galmed announces development of novel LNP cardiac targeted Aramchol formulation

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Jul 16, 2026, 7:30 AM EDT - 4 days ago

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Galmed announces restructured acquisition terms for Colospan

2026-06-22T11:27:49.000Z - 4 weeks ago

Galmed announces restructured acquisition terms for Colospan

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

Jun 22, 2026, 7:00 AM EDT - 4 weeks ago

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

Galmed to acquire Colospan in cash and stock deal

2026-06-08T12:27:05.000Z - 6 weeks ago

Galmed to acquire Colospan in cash and stock deal

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Jun 8, 2026, 8:10 AM EDT - 6 weeks ago

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

2026-06-02T12:19:17.000Z - 6 weeks ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

2026-06-02T12:18:29.000Z - 6 weeks ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Jun 2, 2026, 7:30 AM EDT - 6 weeks ago

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Galmed reports results from first-in-man PK study of Aramchol Meglumine

2026-05-14T11:53:04.000Z - 2 months ago

Galmed reports results from first-in-man PK study of Aramchol Meglumine

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

May 14, 2026, 7:30 AM EDT - 2 months ago

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

2026-05-07T07:22:50.000Z - 2 months ago

Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

May 6, 2026, 7:30 AM EDT - 2 months ago

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Galmed announces research agreement with Ramot at Tel Aviv University

2026-04-14T11:43:26.000Z - 3 months ago

Galmed announces research agreement with Ramot at Tel Aviv University

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Apr 14, 2026, 7:30 AM EDT - 3 months ago

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

2026-04-09T12:36:46.000Z - 3 months ago

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

Galmed announces development of brain penetrating formulation of Aramchol

2026-04-09T12:02:39.000Z - 3 months ago

Galmed announces development of brain penetrating formulation of Aramchol

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Apr 9, 2026, 7:30 AM EDT - 3 months ago

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 31, 2026, 4:15 PM EDT - 3 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026, 4:15 PM EST - 6 months ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed granted new Use Patent related to lead compound Aramchol

2025-12-04T13:35:34.000Z - 8 months ago

Galmed granted new Use Patent related to lead compound Aramchol

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed issues CEO letter to shareholders

2025-12-01T13:40:19.000Z - 8 months ago

Galmed issues CEO letter to shareholders

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 8 months ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 8 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine

2025-11-18T14:47:44.000Z - 8 months ago

Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers

2025-11-17T13:41:03.000Z - 8 months ago

Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 11 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed approves digital asset management strategy

2025-08-25T11:35:22.000Z - 11 months ago

Galmed approves digital asset management strategy

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 11 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed files to sell 7.5M shares of common stock for holders

2025-08-18T21:25:08.000Z - 11 months ago

Galmed files to sell 7.5M shares of common stock for holders

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 1 year ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed’s Aramchol shows “significant” anti-fibrotic effects in PSC models

2025-05-13T12:05:15.000Z - 1 year ago

Galmed’s Aramchol shows “significant” anti-fibrotic effects in PSC models

Biotech Alert: Searches spiking for these stocks today

2025-05-09T15:55:18.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

BOLT CRMD JAZZ KRYS PTN RIGL TECH

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 1 year ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Apr 4, 2024, 5:06 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 26, 2023, 8:30 AM EDT - 3 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 14, 2023, 9:30 AM EDT - 3 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jul 10, 2023, 8:00 AM EDT - 3 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 9, 2023, 7:00 AM EDT - 3 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Jul 7, 2022, 8:27 AM EDT - 4 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022, 7:30 AM EDT - 4 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed announces positive results of Phase 1 study of Amilo-5MER

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:30 AM EST - 5 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Mile111
Mile111 Jul. 20 at 8:16 AM
$GLMD next week delisting 🫡
0 · Reply
Lowlyme
Lowlyme Jul. 19 at 10:52 PM
$GLMD Allen. Divert money from primary drug candidate. Wait 6 months while memories fade. Pay yourself. Repeat.
0 · Reply
Lowlyme
Lowlyme Jul. 19 at 10:27 PM
$GLMD I've seen more UFO's in the past five years than I've heard from Allen. LM
0 · Reply
YaKnowImRight
YaKnowImRight Jul. 17 at 10:06 PM
$GLMD Sitting here wondering exactly what it's gonna take for this to get reasonably valued in the market. A $4.23M MC is absurd for what glmd has.
2 · Reply
Lowlyme
Lowlyme Jul. 17 at 1:43 PM
$GLMD If so I wonder why not just let us know? Anyway, hope so soon. GLTA LM
1 · Reply
madan_shatri
madan_shatri Jul. 17 at 12:57 PM
$GLMD no news about reverse split so it looks like they've got the extension. I am ok on extension rather than reverse split
1 · Reply
Vermont512
Vermont512 Jul. 17 at 9:00 AM
$GLMD I hope the upward trend from yesterday continues today.😉
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Jul. 16 at 11:37 PM
$GLMD on watch
0 · Reply
YaKnowImRight
YaKnowImRight Jul. 16 at 10:33 PM
$GLMD Actually closed up. Can we get a follow-through tomorrow?
0 · Reply
Mile111
Mile111 Jul. 16 at 8:12 PM
$GLMD why this Not going 100 Dollar whyyyyyyyyyyy???????
0 · Reply
never_chase
never_chase Jul. 16 at 7:50 PM
$GLMD Many good news always but the price doesn t go up
0 · Reply
prismmarketview
prismmarketview Jul. 16 at 6:11 PM
$GLMD GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver. The target is cardiac fibrosis, a real unmet need with no approved therapy. https://prismmarketview.com/galmed-aims-its-scd1-inhibitor-at-the-heart-with-a-new-delivery-formulation/
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 5:52 PM
$GLMD just expanded beyond GI — and the long-term opportunity just got bigger. ❤️ Galmed unveiled a new Aramchol-based lipid nanoparticle (LNP) formulation designed for targeted delivery to the heart. 🫀 Developed with Barcode Nanotech using AI-enabled analysis and in vivo screening 🎯 Built to improve selective cardiac delivery, with the goal of advancing therapies for cardiac fibrosis and future cardiometabolic programs See what Wall Street expects next 👉 https://www.zacks.com/stock/research/GLMD/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38834&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38834
0 · Reply
edmark1994
edmark1994 Jul. 16 at 5:17 PM
$GLMD 2 R/S for 10+ years traded for a Pharma Company is OK.. Takes Years
0 · Reply
edmark1994
edmark1994 Jul. 16 at 5:10 PM
$GLMD How This is traded at this levels.. Big Potential heavily shorted Good For Long Run also after R/S or maybe we see 1$ soon Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) completed the acquisition of commercial-stage medical device company Colospan Ltd. on June 22, 2026, aiming to generate top-line revenue faster ------------------------ CG-100 Intraluminal Bypass Device Launch Markets: Initial focus on Germany, Austria, and Switzerland during H2 2026, backed by a dedicated OPS reimbursement code in Germany The CG-100 Intraluminal Bypass Device is positioned to capture a share of a $5 billion to $6 billion total addressable market for colorectal and gastrointestinal surgeries -------------------------- Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestinal development programs.
0 · Reply
Nexttick
Nexttick Jul. 16 at 4:42 PM
$GLMD Good for a hold 🤝
0 · Reply
Mile111
Mile111 Jul. 16 at 4:00 PM
$GLMD from 2000 Dollar to 0.50 Dollar that is great 🤣🤣🤣🤣🤦🤦🤦🤦🤦
1 · Reply
Shakattack31
Shakattack31 Jul. 16 at 3:43 PM
$GLMD thats great
1 · Reply
FibonacciTrader_
FibonacciTrader_ Jul. 16 at 3:05 PM
Real-Time Watchlist | Stocks to Watch Today Keep these names on your radar: $KAPA -Needs to hold $0.35 Phase 1 PR remains the key catalyst. $SEGG -Watching for $0.85 Prediction market news could drive momentum. $LIMN -Recent Form 4 filing. Strong day-trade candidate. $ATPC -High-risk momentum play. Previously spiked to $4.90. $GLMD -Must reclaim and hold $0.62 A breakout above this level could trigger the next move. Stay disciplined, trade the price action, and let the market confirm the setup before chasing momentum. Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.
0 · Reply
LewisDaKat
LewisDaKat Jul. 16 at 3:00 PM
$GLMD Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol https://marketwirenews.com/stock/glmd/news/galmed-announces-the-breakthrough-development-of-nov-6117121673597812.html?utm_source=stocktwits
1 · Reply
edmark1994
edmark1994 Jul. 16 at 2:51 PM
$GLMD they have a product ready for sale in Europe Do some research CG-100 Intraluminal Bypass Device and + this news.. worth a shot at 0.50-0.45 levels
1 · Reply
Mile111
Mile111 Jul. 16 at 2:43 PM
$GLMD ITS to late delisting is comming 💩🗑️
0 · Reply